These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 6645208)

  • 21. Effect of prolonged bedrest on the propensity for renal stone formation.
    Hwang TI; Hill K; Schneider V; Pak CY
    J Clin Endocrinol Metab; 1988 Jan; 66(1):109-12. PubMed ID: 3335600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.
    Krieger NS; Asplin JR; Frick KK; Granja I; Culbertson CD; Ng A; Grynpas MD; Bushinsky DA
    J Am Soc Nephrol; 2015 Dec; 26(12):3001-8. PubMed ID: 25855777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raising urinary citrate lowers calcium oxalate and calcium phosphate crystal formation in whole urine.
    Hallson PC; Rose GA; Sulaiman S
    Urol Int; 1983; 38(3):179-81. PubMed ID: 6868215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
    Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
    Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sodium citrate, potassium citrate, and citric acid in preventing experimental calcium oxalate urolithiasis in rats.
    Ogawa Y; Tanaka T; Yamaguchi K; Morozumi M; Kitagawa R
    Hinyokika Kiyo; 1987 Nov; 33(11):1772-7. PubMed ID: 3445859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 24-Hour Urinary Chemistries and Kidney Stone Risk.
    Ferraro PM; Taylor EN; Curhan GC
    Am J Kidney Dis; 2024 Aug; 84(2):164-169. PubMed ID: 38583757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of orange juice consumption on urinary stone risk factors.
    Wabner CL; Pak CY
    J Urol; 1993 Jun; 149(6):1405-8. PubMed ID: 8501777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction.
    Lindberg J; Harvey J; Pak CY
    J Urol; 1990 Feb; 143(2):248-51. PubMed ID: 2299712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of meal on the physiological and physicochemical actions of potassium citrate.
    Pak CY; Oh MS; Baker S; Morris JS
    J Urol; 1991 Sep; 146(3):803-5. PubMed ID: 1875495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seasonal variations in urinary risk factors among patients with nephrolithiasis.
    Stuart RO 2nd ; Hill K; Poindexter J; Pak CY
    J Lithotr Stone Dis; 1991 Jan; 3(1):18-27. PubMed ID: 11536932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurements of urinary state of saturation with respect to calcium oxalate and brushite (CaHPO4.2H2O) in renal stone formers.
    Sriboonlue P; Prasongwattana V; Tungsanga K; Sitprija V
    J Med Assoc Thai; 1990 Dec; 73(12):684-9. PubMed ID: 2086716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physicochemical action of potassium-magnesium citrate in nephrolithiasis.
    Pak CY; Koenig K; Khan R; Haynes S; Padalino P
    J Bone Miner Res; 1992 Mar; 7(3):281-5. PubMed ID: 1585829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary Tamm-Horsfall protein increased after potassium citrate therapy in calcium stone formers.
    Fuselier HA; Ward DM; Lindberg JS; Allen JM; Husserl FE; Marcucci PA; Cole FE; Turnipseed J; Alam J; Kok DJ
    Urology; 1995 Jun; 45(6):942-6. PubMed ID: 7771027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis.
    Nicar MJ; Peterson R; Pak CY
    J Urol; 1984 Mar; 131(3):430-3. PubMed ID: 6699979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Influence of urinary citrate levels on spontaneous calcium oxalate dihydrate crystalluria].
    Hassani MA; Hennequin C; Lacour B; Daudon M
    Prog Urol; 2005 Sep; 15(4):650-5. PubMed ID: 16459680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of citrate complexes in preventing urolithiasis.
    Ashby RA; Sleet RJ
    Clin Chim Acta; 1992 Sep; 210(3):157-65. PubMed ID: 1468138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citric acid or citrates in urine: which should we focus on in the prevention of calcium oxalate crystals and stones?
    Laube N; Jansen B; Hesse A
    Urol Res; 2002 Oct; 30(5):336-41. PubMed ID: 12389124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of citrate on hydroxyapatite induced calcium oxalate crystallization and on the formation of calcium phosphate crystals.
    Berg C; Tiselius HG
    Urol Res; 1989; 17(3):167-72. PubMed ID: 2546314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.